Lindsey A Herrel1, Samuel R Kaufman1, Phyllis Yan1, David C Miller1, Florian R Schroeck2, Ted A Skolarus3, Vahakn B Shahinian4, Brent K Hollenbeck5. 1. Dow Division for Urological Health Services Research, Department of Urology, University of Michigan, Ann Arbor, Michigan. 2. White River Junction VA Medical Center, White River Junction, Vermont, The Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth College, Section of Urology and Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire. 3. Dow Division for Urological Health Services Research, Department of Urology, University of Michigan, Ann Arbor, Michigan; VA Health Services Research & Development Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, Michigan. 4. Kidney Epidemiology Cost Center, University of Michigan, Ann Arbor, Michigan. 5. Dow Division for Urological Health Services Research, Department of Urology, University of Michigan, Ann Arbor, Michigan. Electronic address: bhollen@umich.edu.
Abstract
PURPOSE: The delivery of high quality prostate cancer care is increasingly important for health systems, physicians and patients. Integrated delivery systems may have the greatest ability to deliver high quality, efficient care. We sought to understand the association between health care integration and quality of prostate cancer care. MATERIALS AND METHODS: We used SEER-Medicare data to perform a retrospective cohort study of men older than age 65 with prostate cancer diagnosed between 2007 and 2011. We defined integration within a health care market based on the number of discharges from a top 100 integrated delivery system, and compared rates of adherence to well accepted prostate cancer quality measures in markets with no integration vs full integration (greater than 90% of discharges from an integrated system). RESULTS: The average man treated in a fully integrated market was more likely to receive pretreatment counseling by a urologist and radiation oncologist (62.6% vs 60.3%, p=0.03), avoid inappropriate imaging (72.2% avoided vs 60.6%, p <0.001), avoid treatment when life expectancy was less than 10 years (23.7% vs 17.3%, p <0.001) and avoid multiple hospitalizations in the last 30 days of life (50.2% vs 43.6%, p=0.001) than when treated in markets with no integration. Additionally, patients treated in fully integrated markets were more likely to have complete adherence to all eligible quality measures (OR 1.38, 95% CI 1.27-1.50). CONCLUSIONS: Integrated systems are associated with improved adherence to several prostate cancer quality measures. Expansion of the integrated health care model may facilitate greater delivery of high quality prostate cancer care. Copyright Â
PURPOSE: The delivery of high quality prostate cancer care is increasingly important for health systems, physicians and patients. Integrated delivery systems may have the greatest ability to deliver high quality, efficient care. We sought to understand the association between health care integration and quality of prostate cancer care. MATERIALS AND METHODS: We used SEER-Medicare data to perform a retrospective cohort study of men older than age 65 with prostate cancer diagnosed between 2007 and 2011. We defined integration within a health care market based on the number of discharges from a top 100 integrated delivery system, and compared rates of adherence to well accepted prostate cancer quality measures in markets with no integration vs full integration (greater than 90% of discharges from an integrated system). RESULTS: The average man treated in a fully integrated market was more likely to receive pretreatment counseling by a urologist and radiation oncologist (62.6% vs 60.3%, p=0.03), avoid inappropriate imaging (72.2% avoided vs 60.6%, p <0.001), avoid treatment when life expectancy was less than 10 years (23.7% vs 17.3%, p <0.001) and avoid multiple hospitalizations in the last 30 days of life (50.2% vs 43.6%, p=0.001) than when treated in markets with no integration. Additionally, patients treated in fully integrated markets were more likely to have complete adherence to all eligible quality measures (OR 1.38, 95% CI 1.27-1.50). CONCLUSIONS: Integrated systems are associated with improved adherence to several prostate cancer quality measures. Expansion of the integrated health care model may facilitate greater delivery of high quality prostate cancer care. Copyright Â
Authors: Gabriel A Brooks; Ling Li; Dhruv B Sharma; Jane C Weeks; Michael J Hassett; K Robin Yabroff; Deborah Schrag Journal: J Natl Cancer Inst Date: 2013-03-12 Impact factor: 13.506
Authors: David C Miller; Benjamin A Spencer; Rajal B Shah; Jamie Ritchey; Andrew K Stewart; E Greer Gay; Rodney L Dunn; John T Wei; Mark S Litwin Journal: Cancer Date: 2007-06-15 Impact factor: 6.860
Authors: David C Miller; Benjamin A Spencer; Jamie Ritchey; Andrew K Stewart; Rodney L Dunn; Howard M Sandler; John T Wei; Mark S Litwin Journal: Med Care Date: 2007-05 Impact factor: 2.983
Authors: Florian R Schroeck; Samuel R Kaufman; Bruce L Jacobs; Ted A Skolarus; John M Hollingsworth; Vahakn B Shahinian; Brent K Hollenbeck Journal: J Urol Date: 2013-10-19 Impact factor: 7.450
Authors: Hannah T Neprash; Michael E Chernew; Andrew L Hicks; Teresa Gibson; J Michael McWilliams Journal: JAMA Intern Med Date: 2015-12 Impact factor: 21.873
Authors: J Michael McWilliams; Michael E Chernew; Alan M Zaslavsky; Pasha Hamed; Bruce E Landon Journal: JAMA Intern Med Date: 2013-08-12 Impact factor: 21.873
Authors: Leif I Solberg; Stephen E Asche; Stephen M Shortell; Robin R Gillies; Nancy Taylor; L Gregory Pawlson; Sarah Hudson Scholle; M Rashell Young Journal: Am J Manag Care Date: 2009-06-01 Impact factor: 2.229
Authors: Davide Gori; Rajendra Dulal; Douglas W Blayney; James D Brooks; Maria P Fantini; Kathryn M McDonald; Tina Hernandez-Boussard Journal: Jt Comm J Qual Patient Saf Date: 2018-09-18
Authors: Scott M Glaser; Ronny Kalash; Dante R Bongiorni; Mark S Roberts; Goundappa K Balasubramani; Bruce L Jacobs; Sushil Beriwal; Dwight E Heron; Joel S Greenberger Journal: In Vivo Date: 2018 Jan-Feb Impact factor: 2.155
Authors: Jonathan Li; Zaojun Ye; James M Dupree; Brent K Hollenbeck; Hye Sung Min; Deborah Kaye; Lindsey A Herrel; David C Miller; Chad Ellimoottil Journal: Ann Surg Oncol Date: 2017-12-29 Impact factor: 5.344
Authors: Tudor Borza; Samuel R Kaufman; Phyllis Yan; Lindsey A Herrel; Amy N Luckenbaugh; David C Miller; Ted A Skolarus; Bruce L Jacobs; John M Hollingsworth; Edward C Norton; Vahakn B Shahinian; Brent K Hollenbeck Journal: Cancer Date: 2017-10-20 Impact factor: 6.860
Authors: Sue M Evans; Jeremy L Millar; Caroline M Moore; John D Lewis; Hartwig Huland; Fanny Sampurno; Sarah E Connor; Paul Villanti; Mark S Litwin Journal: BMJ Open Date: 2017-11-28 Impact factor: 2.692
Authors: Lindsey A Herrel; Ziwei Zhu; Jennifer J Griggs; Deborah R Kaye; James M Dupree; Chandy S Ellimoottil; David C Miller Journal: JCO Oncol Pract Date: 2020-02-18
Authors: Richard Mutemwa; Susannah H Mayhew; Charlotte E Warren; Timothy Abuya; Charity Ndwiga; Jackline Kivunaga Journal: Health Policy Plan Date: 2017-11-01 Impact factor: 3.344